APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mucopolysaccharidosis II

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mucopolysaccharidosis II Market Outlook and Growth Opportunities 2026

26 December 2025195 pages

Choose your research edition.

Industry ResearchMucopolysaccharidosis II Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Mucopolysaccharidosis II Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Mucopolysaccharidosis II Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mucopolysaccharidosis II Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Mucopolysaccharidosis II Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Mucopolysaccharidosis II market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mucopolysaccharidosis II is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mucopolysaccharidosis II is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mucopolysaccharidosis II is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mucopolysaccharidosis II market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mucopolysaccharidosis II market include Takeda, Sangamo BioSciences, Inc., RegenxBio Inc., Laboratorios Del Dr. Esteve S.A., JCR Pharmaceuticals Co., Ltd., Inventiva, Green Cross Corporation, Bioasis Technologies Inc. and ArmaGen Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Mucopolysaccharidosis II market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mucopolysaccharidosis II and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mucopolysaccharidosis II sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mucopolysaccharidosis II market size, projected growth trends, production technologies, key applications, and end-use industries.

Mucopolysaccharidosis II Segment by Company

Takeda

Sangamo BioSciences, Inc.

RegenxBio Inc.

Laboratorios Del Dr. Esteve S.A.

JCR Pharmaceuticals Co., Ltd.

Inventiva

Green Cross Corporation

Bioasis Technologies Inc.

ArmaGen Inc.

AngioChem Inc.

Alexion Pharmaceuticals, Inc.

Mucopolysaccharidosis II Segment by Type

AGT-182

DUOC-01

EGT-301

JR-032

JR-141

Others

Mucopolysaccharidosis II Segment by Application

Clinic

Hospital

Research Center

Others

Mucopolysaccharidosis II Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mucopolysaccharidosis II status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Mucopolysaccharidosis II market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mucopolysaccharidosis II significant trends, drivers, influence factors in global and regions.

6. To analyze Mucopolysaccharidosis II competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mucopolysaccharidosis II market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mucopolysaccharidosis II and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mucopolysaccharidosis II.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Mucopolysaccharidosis II market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mucopolysaccharidosis II industry.

Chapter 3: Detailed analysis of Mucopolysaccharidosis II manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Mucopolysaccharidosis II in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Mucopolysaccharidosis II in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mucopolysaccharidosis II Industry Trends Table 2. Mucopolysaccharidosis II Industry Drivers Table 3. Mucopolysaccharidosis II Industry Opportunities and Challenges Table 4. Mucopolysaccharidosis II Industry Restraints Table 5. Global Mucopolysaccharidosis II Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mucopolysaccharidosis II Revenue Share by Company (2021-2026) Table 7. Global Mucopolysaccharidosis II Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Mucopolysaccharidosis II Sales Volume Share by Company (2021-2026) Table 9. Global Mucopolysaccharidosis II Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Mucopolysaccharidosis II Company Ranking, (2024-2026) & (USD Million) Table 11. Global Mucopolysaccharidosis II Key Company Manufacturing Base & Headquarters Table 12. Global Mucopolysaccharidosis II Company, Product Type & Application Table 13. Global Mucopolysaccharidosis II Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Mucopolysaccharidosis II by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of AGT-182 Table 18. Significant Companies of DUOC-01 Table 19. Significant Companies of EGT-301 Table 20. Significant Companies of JR-032 Table 21. Significant Companies of JR-141 Table 22. Significant Companies of Others Table 23. Global Mucopolysaccharidosis II Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Mucopolysaccharidosis II Sales Volume by Type (2021-2026) & (W Units) Table 25. Global Mucopolysaccharidosis II Sales Volume by Type (2027-2032) & (W Units) Table 26. Global Mucopolysaccharidosis II Sales Volume Share by Type (2021-2026) Table 27. Global Mucopolysaccharidosis II Sales Volume Share by Type (2027-2032) Table 28. Global Mucopolysaccharidosis II Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Mucopolysaccharidosis II Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Mucopolysaccharidosis II Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Mucopolysaccharidosis II Sales Value Share by Type (2021-2026) Table 32. Global Mucopolysaccharidosis II Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Clinic Table 34. Significant Companies of Hospital Table 35. Significant Companies of Research Center Table 36. Significant Companies of Others Table 37. Global Mucopolysaccharidosis II Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Mucopolysaccharidosis II Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Mucopolysaccharidosis II Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Mucopolysaccharidosis II Sales Volume Share by Application (2021-2026) Table 41. Global Mucopolysaccharidosis II Sales Volume Share by Application (2027-2032) Table 42. Global Mucopolysaccharidosis II Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Mucopolysaccharidosis II Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Mucopolysaccharidosis II Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Mucopolysaccharidosis II Sales Value Share by Application (2021-2026) Table 46. Global Mucopolysaccharidosis II Sales Value Share by Application (2027-2032) Table 47. Global Mucopolysaccharidosis II Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Mucopolysaccharidosis II Sales by Region (2021-2026) & (W Units) Table 49. Global Mucopolysaccharidosis II Sales Market Share by Region (2021-2026) Table 50. Global Mucopolysaccharidosis II Sales by Region (2027-2032) & (W Units) Table 51. Global Mucopolysaccharidosis II Sales Market Share by Region (2027-2032) Table 52. Global Mucopolysaccharidosis II Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Mucopolysaccharidosis II Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Mucopolysaccharidosis II Sales Value Share by Region (2021-2026) Table 55. Global Mucopolysaccharidosis II Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Mucopolysaccharidosis II Sales Value Share by Region (2027-2032) Table 57. Global Mucopolysaccharidosis II Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Mucopolysaccharidosis II Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Mucopolysaccharidosis II Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Mucopolysaccharidosis II Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Mucopolysaccharidosis II Sales by Country (2021-2026) & (W Units) Table 62. Global Mucopolysaccharidosis II Sales Market Share by Country (2021-2026) Table 63. Global Mucopolysaccharidosis II Sales by Country (2027-2032) & (W Units) Table 64. Global Mucopolysaccharidosis II Sales Market Share by Country (2027-2032) Table 65. Global Mucopolysaccharidosis II Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Mucopolysaccharidosis II Sales Value Market Share by Country (2021-2026) Table 67. Global Mucopolysaccharidosis II Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Mucopolysaccharidosis II Sales Value Market Share by Country (2027-2032) Table 69. Takeda Company Information Table 70. Takeda Business Overview Table 71. Takeda Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Takeda Mucopolysaccharidosis II Product Portfolio Table 73. Takeda Recent Development Table 74. Sangamo BioSciences, Inc. Company Information Table 75. Sangamo BioSciences, Inc. Business Overview Table 76. Sangamo BioSciences, Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sangamo BioSciences, Inc. Mucopolysaccharidosis II Product Portfolio Table 78. Sangamo BioSciences, Inc. Recent Development Table 79. RegenxBio Inc. Company Information Table 80. RegenxBio Inc. Business Overview Table 81. RegenxBio Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. RegenxBio Inc. Mucopolysaccharidosis II Product Portfolio Table 83. RegenxBio Inc. Recent Development Table 84. Laboratorios Del Dr. Esteve S.A. Company Information Table 85. Laboratorios Del Dr. Esteve S.A. Business Overview Table 86. Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Product Portfolio Table 88. Laboratorios Del Dr. Esteve S.A. Recent Development Table 89. JCR Pharmaceuticals Co., Ltd. Company Information Table 90. JCR Pharmaceuticals Co., Ltd. Business Overview Table 91. JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Product Portfolio Table 93. JCR Pharmaceuticals Co., Ltd. Recent Development Table 94. Inventiva Company Information Table 95. Inventiva Business Overview Table 96. Inventiva Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Inventiva Mucopolysaccharidosis II Product Portfolio Table 98. Inventiva Recent Development Table 99. Green Cross Corporation Company Information Table 100. Green Cross Corporation Business Overview Table 101. Green Cross Corporation Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Green Cross Corporation Mucopolysaccharidosis II Product Portfolio Table 103. Green Cross Corporation Recent Development Table 104. Bioasis Technologies Inc. Company Information Table 105. Bioasis Technologies Inc. Business Overview Table 106. Bioasis Technologies Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bioasis Technologies Inc. Mucopolysaccharidosis II Product Portfolio Table 108. Bioasis Technologies Inc. Recent Development Table 109. ArmaGen Inc. Company Information Table 110. ArmaGen Inc. Business Overview Table 111. ArmaGen Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. ArmaGen Inc. Mucopolysaccharidosis II Product Portfolio Table 113. ArmaGen Inc. Recent Development Table 114. AngioChem Inc. Company Information Table 115. AngioChem Inc. Business Overview Table 116. AngioChem Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. AngioChem Inc. Mucopolysaccharidosis II Product Portfolio Table 118. AngioChem Inc. Recent Development Table 119. Alexion Pharmaceuticals, Inc. Company Information Table 120. Alexion Pharmaceuticals, Inc. Business Overview Table 121. Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Product Portfolio Table 123. Alexion Pharmaceuticals, Inc. Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Mucopolysaccharidosis II Distributors List Table 127. Mucopolysaccharidosis II Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Mucopolysaccharidosis II Product Image Figure 2. Global Mucopolysaccharidosis II Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 4. Global Mucopolysaccharidosis II Sales (2021-2032) & (W Units) Figure 5. Global Mucopolysaccharidosis II Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Mucopolysaccharidosis II Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. AGT-182 Image Figure 10. DUOC-01 Image Figure 11. EGT-301 Image Figure 12. JR-032 Image Figure 13. JR-141 Image Figure 14. Others Image Figure 15. Global Mucopolysaccharidosis II Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Mucopolysaccharidosis II Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Mucopolysaccharidosis II Sales Volume Share by Type (2021-2032) Figure 18. Global Mucopolysaccharidosis II Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Mucopolysaccharidosis II Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Mucopolysaccharidosis II Sales Value Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Research Center Image Figure 24. Others Image Figure 25. Global Mucopolysaccharidosis II Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Mucopolysaccharidosis II Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Mucopolysaccharidosis II Sales Volume Share by Application (2021-2032) Figure 28. Global Mucopolysaccharidosis II Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Mucopolysaccharidosis II Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Mucopolysaccharidosis II Sales Value Share by Application (2021-2032) Figure 31. Global Mucopolysaccharidosis II Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Mucopolysaccharidosis II Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Mucopolysaccharidosis II Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Mucopolysaccharidosis II Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 36. North America Mucopolysaccharidosis II Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Mucopolysaccharidosis II Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Mucopolysaccharidosis II Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 42. South America Mucopolysaccharidosis II Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Mucopolysaccharidosis II Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Mucopolysaccharidosis II Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Mucopolysaccharidosis II Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Mucopolysaccharidosis II Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • AGT-182
  • DUOC-01
  • EGT-301
  • JR-032
  • JR-141
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Takeda
  • Sangamo BioSciences, Inc.
  • RegenxBio Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • JCR Pharmaceuticals Co., Ltd.
  • Inventiva
  • Green Cross Corporation
  • Bioasis Technologies Inc.
  • ArmaGen Inc.
  • AngioChem Inc.
  • Alexion Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Mucopolysaccharidosis II Sales Value (2021-2032)
  4. 1.2.2 Global Mucopolysaccharidosis II Sales Volume (2021-2032)
  5. 1.2.3 Global Mucopolysaccharidosis II Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Mucopolysaccharidosis II Market Dynamics
  1. 2.1 Mucopolysaccharidosis II Industry Trends
  2. 2.2 Mucopolysaccharidosis II Industry Drivers
  3. 2.3 Mucopolysaccharidosis II Industry Opportunities and Challenges
  4. 2.4 Mucopolysaccharidosis II Industry Restraints
3 Mucopolysaccharidosis II Market by Company
  1. 3.1 Global Mucopolysaccharidosis II Company Revenue Ranking in 2025
  2. 3.2 Global Mucopolysaccharidosis II Revenue by Company (2021-2026)
  3. 3.3 Global Mucopolysaccharidosis II Sales Volume by Company (2021-2026)
  4. 3.4 Global Mucopolysaccharidosis II Average Price by Company (2021-2026)
  5. 3.5 Global Mucopolysaccharidosis II Company Ranking (2024-2026)
  6. 3.6 Global Mucopolysaccharidosis II Company Manufacturing Base and Headquarters
  7. 3.7 Global Mucopolysaccharidosis II Company Product Type and Application
  8. 3.8 Global Mucopolysaccharidosis II Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Mucopolysaccharidosis II Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Mucopolysaccharidosis II Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Mucopolysaccharidosis II Market by Type
  1. 4.1 Mucopolysaccharidosis II Type Introduction
  2. 4.1.1 AGT-182
  3. 4.1.2 DUOC-01
  4. 4.1.3 EGT-301
  5. 4.1.4 JR-032
  6. 4.1.5 JR-141
  7. 4.1.6 Others
  8. 4.2 Global Mucopolysaccharidosis II Sales Volume by Type
  9. 4.2.1 Global Mucopolysaccharidosis II Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Mucopolysaccharidosis II Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Mucopolysaccharidosis II Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Mucopolysaccharidosis II Sales Value by Type
  13. 4.3.1 Global Mucopolysaccharidosis II Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Mucopolysaccharidosis II Sales Value by Type (2021-2032)
  15. 4.3.3 Global Mucopolysaccharidosis II Sales Value Share by Type (2021-2032)
5 Mucopolysaccharidosis II Market by Application
  1. 5.1 Mucopolysaccharidosis II Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.1.4 Others
  6. 5.2 Global Mucopolysaccharidosis II Sales Volume by Application
  7. 5.2.1 Global Mucopolysaccharidosis II Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Mucopolysaccharidosis II Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Mucopolysaccharidosis II Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Mucopolysaccharidosis II Sales Value by Application
  11. 5.3.1 Global Mucopolysaccharidosis II Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Mucopolysaccharidosis II Sales Value by Application (2021-2032)
  13. 5.3.3 Global Mucopolysaccharidosis II Sales Value Share by Application (2021-2032)
6 Mucopolysaccharidosis II Regional Sales and Value Analysis
  1. 6.1 Global Mucopolysaccharidosis II Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mucopolysaccharidosis II Sales by Region (2021-2032)
  3. 6.2.1 Global Mucopolysaccharidosis II Sales by Region: 2021-2026
  4. 6.2.2 Global Mucopolysaccharidosis II Sales by Region (2027-2032)
  5. 6.3 Global Mucopolysaccharidosis II Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Mucopolysaccharidosis II Sales Value by Region (2021-2032)
  7. 6.4.1 Global Mucopolysaccharidosis II Sales Value by Region: 2021-2026
  8. 6.4.2 Global Mucopolysaccharidosis II Sales Value by Region (2027-2032)
  9. 6.5 Global Mucopolysaccharidosis II Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Mucopolysaccharidosis II Sales Value (2021-2032)
  12. 6.6.2 North America Mucopolysaccharidosis II Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Mucopolysaccharidosis II Sales Value (2021-2032)
  15. 6.7.2 Europe Mucopolysaccharidosis II Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Mucopolysaccharidosis II Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Mucopolysaccharidosis II Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Mucopolysaccharidosis II Sales Value (2021-2032)
  21. 6.9.2 South America Mucopolysaccharidosis II Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Mucopolysaccharidosis II Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Mucopolysaccharidosis II Sales Value Share by Country, 2025 VS 2032
7 Mucopolysaccharidosis II Country-level Sales and Value Analysis
  1. 7.1 Global Mucopolysaccharidosis II Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mucopolysaccharidosis II Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Mucopolysaccharidosis II Sales by Country (2021-2032)
  4. 7.3.1 Global Mucopolysaccharidosis II Sales by Country (2021-2026)
  5. 7.3.2 Global Mucopolysaccharidosis II Sales by Country (2027-2032)
  6. 7.4 Global Mucopolysaccharidosis II Sales Value by Country (2021-2032)
  7. 7.4.1 Global Mucopolysaccharidosis II Sales Value by Country (2021-2026)
  8. 7.4.2 Global Mucopolysaccharidosis II Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Mucopolysaccharidosis II Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Mucopolysaccharidosis II Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Mucopolysaccharidosis II Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Mucopolysaccharidosis II Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sangamo BioSciences, Inc.
  8. 8.2.1 Sangamo BioSciences, Inc. Company Information
  9. 8.2.2 Sangamo BioSciences, Inc. Business Overview
  10. 8.2.3 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sangamo BioSciences, Inc. Mucopolysaccharidosis II Product Portfolio
  12. 8.2.5 Sangamo BioSciences, Inc. Recent Developments
  13. 8.3 RegenxBio Inc.
  14. 8.3.1 RegenxBio Inc. Company Information
  15. 8.3.2 RegenxBio Inc. Business Overview
  16. 8.3.3 RegenxBio Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 RegenxBio Inc. Mucopolysaccharidosis II Product Portfolio
  18. 8.3.5 RegenxBio Inc. Recent Developments
  19. 8.4 Laboratorios Del Dr. Esteve S.A.
  20. 8.4.1 Laboratorios Del Dr. Esteve S.A. Company Information
  21. 8.4.2 Laboratorios Del Dr. Esteve S.A. Business Overview
  22. 8.4.3 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Laboratorios Del Dr. Esteve S.A. Mucopolysaccharidosis II Product Portfolio
  24. 8.4.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
  25. 8.5 JCR Pharmaceuticals Co., Ltd.
  26. 8.5.1 JCR Pharmaceuticals Co., Ltd. Company Information
  27. 8.5.2 JCR Pharmaceuticals Co., Ltd. Business Overview
  28. 8.5.3 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 JCR Pharmaceuticals Co., Ltd. Mucopolysaccharidosis II Product Portfolio
  30. 8.5.5 JCR Pharmaceuticals Co., Ltd. Recent Developments
  31. 8.6 Inventiva
  32. 8.6.1 Inventiva Company Information
  33. 8.6.2 Inventiva Business Overview
  34. 8.6.3 Inventiva Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Inventiva Mucopolysaccharidosis II Product Portfolio
  36. 8.6.5 Inventiva Recent Developments
  37. 8.7 Green Cross Corporation
  38. 8.7.1 Green Cross Corporation Company Information
  39. 8.7.2 Green Cross Corporation Business Overview
  40. 8.7.3 Green Cross Corporation Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Green Cross Corporation Mucopolysaccharidosis II Product Portfolio
  42. 8.7.5 Green Cross Corporation Recent Developments
  43. 8.8 Bioasis Technologies Inc.
  44. 8.8.1 Bioasis Technologies Inc. Company Information
  45. 8.8.2 Bioasis Technologies Inc. Business Overview
  46. 8.8.3 Bioasis Technologies Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bioasis Technologies Inc. Mucopolysaccharidosis II Product Portfolio
  48. 8.8.5 Bioasis Technologies Inc. Recent Developments
  49. 8.9 ArmaGen Inc.
  50. 8.9.1 ArmaGen Inc. Company Information
  51. 8.9.2 ArmaGen Inc. Business Overview
  52. 8.9.3 ArmaGen Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ArmaGen Inc. Mucopolysaccharidosis II Product Portfolio
  54. 8.9.5 ArmaGen Inc. Recent Developments
  55. 8.10 AngioChem Inc.
  56. 8.10.1 AngioChem Inc. Company Information
  57. 8.10.2 AngioChem Inc. Business Overview
  58. 8.10.3 AngioChem Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AngioChem Inc. Mucopolysaccharidosis II Product Portfolio
  60. 8.10.5 AngioChem Inc. Recent Developments
  61. 8.11 Alexion Pharmaceuticals, Inc.
  62. 8.11.1 Alexion Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Alexion Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Alexion Pharmaceuticals, Inc. Mucopolysaccharidosis II Product Portfolio
  66. 8.11.5 Alexion Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Mucopolysaccharidosis II Value Chain Analysis
  2. 9.1.1 Mucopolysaccharidosis II Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Mucopolysaccharidosis II Sales Mode & Process
  6. 9.2 Mucopolysaccharidosis II Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Mucopolysaccharidosis II Distributors
  9. 9.2.3 Mucopolysaccharidosis II Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst